Display options
Cite
Oh H, Eliassen AH, Wang M, et al. Expression of estrogen receptor, progesterone receptor, and Ki67 in normal breast tissue in relation to subsequent risk of breast cancer. NPJ Breast Cancer. 2016;2doi: 10.1038/npjbcancer.2016.32.
Oh, H., Eliassen, A. H., Wang, M., Smith-Warner, S. A., Beck, A. H., Schnitt, S. J., Collins, L. C., Connolly, J. L., Montaser-Kouhsari, L., Polyak, K., & Tamimi, R. M. (2016). Expression of estrogen receptor, progesterone receptor, and Ki67 in normal breast tissue in relation to subsequent risk of breast cancer. NPJ breast cancer, 2. https://doi.org/10.1038/npjbcancer.2016.32
Oh, Hannah, et al. "Expression of estrogen receptor, progesterone receptor, and Ki67 in normal breast tissue in relation to subsequent risk of breast cancer." NPJ breast cancer vol. 2 (2016). doi: https://doi.org/10.1038/npjbcancer.2016.32
Oh H, Eliassen AH, Wang M, Smith-Warner SA, Beck AH, Schnitt SJ, Collins LC, Connolly JL, Montaser-Kouhsari L, Polyak K, Tamimi RM. Expression of estrogen receptor, progesterone receptor, and Ki67 in normal breast tissue in relation to subsequent risk of breast cancer. NPJ Breast Cancer. 2016;2. doi: 10.1038/npjbcancer.2016.32. Epub 2016 Oct 26. PMID: 28111631; PMCID: PMC5243126.
Copy Download .nbib Format: NLM
Share it on

NPJ Breast Cancer. 2016;2. doi: 10.1038/npjbcancer.2016.32. Epub 2016 Oct 26.

Expression of estrogen receptor, progesterone receptor, and Ki67 in normal breast tissue in relation to subsequent risk of breast cancer.

NPJ breast cancer

Hannah Oh, A Heather Eliassen, Molin Wang, Stephanie A Smith-Warner, Andrew H Beck, Stuart J Schnitt, Laura C Collins, James L Connolly, Laleh Montaser-Kouhsari, Kornelia Polyak, Rulla M Tamimi

Affiliations

  1. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA; Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
  2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
  3. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
  4. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
  5. Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.
  6. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.

PMID: 28111631 PMCID: PMC5243126 DOI: 10.1038/npjbcancer.2016.32

Abstract

Although expression of estrogen receptor (ER), progesterone receptor (PR), and cell proliferation marker Ki67 serve as predictive and prognostic factors in breast cancers, little is known about their roles in normal breast tissue. Here in a nested case-control study within the Nurses' Health Studies (90 cases, 297 controls), we evaluated their expression levels in normal breast epithelium in relation to subsequent breast cancer risk among women with benign breast disease. Tissue microarrays were constructed using cores obtained from benign biopsies containing normal terminal duct lobular units and immunohistochemical stained for these markers. We found PR and Ki67 expression was non-significantly but positively associated with subsequent breast cancer risk, whereas ER expression was non-significantly inversely associated. After stratifying by lesion subtype, Ki67 was significantly associated with higher risk among women with proliferative lesions with atypical hyperplasia. However, given the small sample size, further studies are required to confirm these results.

Conflict of interest statement

The authors declare no conflict of interest.

References

  1. Lancet. 1999 Nov 20;354(9192):1787-8 - PubMed
  2. Cancer Res. 1989 Jun 1;49(11):2999-3006 - PubMed
  3. Cancer Res. 1991 Apr 1;51(7):1817-22 - PubMed
  4. Breast Cancer Res. 2002;4(5):197-201 - PubMed
  5. Cancer Res. 1992 May 1;52(9):2597-602 - PubMed
  6. BMC Cancer. 2008 May 08;8:130 - PubMed
  7. Cancer Res. 1999 Sep 1;59(17):4276-84 - PubMed
  8. Breast Cancer Res Treat. 2010 Jun;121(2):431-7 - PubMed
  9. Breast Cancer Res Treat. 2011 Jul;128(1):243-50 - PubMed
  10. Cancer Res. 1994 Feb 15;54(4):993-7 - PubMed

Publication Types

Grant support